DiaDx-Liquid Biopsy for personalized cancer medicine Email Formats
Biotechnology Research • 
Montpellier, Occitanie, France • 1-10 Employees
Key Contact at DiaDx-Liquid Biopsy for personalized cancer medicine
Thierry Drugeot
CEO
Company overview
| Headquarters | 208 rue des apothicaires, Montpellier, Veuillez choisir… 34298, FR |
| Website | |
| SIC | 873 |
| Keywords | Personalized Medicine, Cancer, Precision Medicine, Liquid Biopsy, Biomarker, Circulating Cell-Free Dna |
| Founded | 2015 |
| Employees | 1-10 |
About DiaDx-Liquid Biopsy for personalized cancer medicine
DiaDx focuses on the development of alternative analysis systems in oncology based on the use of circulating DNA as a diagnostic tool. DiaDx offers a revolutionary advance for personalized cancer care. The IntPlex(R) test based on a simple blood test developed by DiaDx affords detection and identification of tumor mutations and therefore may replace tests performed on tumor tissues such as biopsy. IntPlex(R) is the unique multimarker test for qualitatively and quantitatively analyzing circulating DNA providing to physicians, patients, pharmaceutical companies and payers real benefits. This technology is functional for solid tumor malignancies (colon, melanoma, prostate cancer, breast cancer, lung cancer ...).
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
DiaDx-Liquid Biopsy for personalized cancer medicine has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
DiaDx-Liquid Biopsy for personalized cancer medicine has never raised funding before.
United Arab Emirates
Austria
United States
Canada
Frequently asked questions
4.8
40,000 users
